PeptideStack
5.2kquestions
20kanswers
220users

My cagrilintide vial sat at room temperature for twenty-eight days — is testing worth it before use?

Asked 29 Oct 2024Modified 17 months agoViewed 34k times
39

What I have: cagrilintide · room temperature · twenty-eight days.

I would rather over-plan the first cycle and simplify later.

I am prepared to do the work if someone can tell me which work matters.

How do I make this decision on evidence rather than on feel?

cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

524 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
shareeditfollowflag
KL
askedkirsi_lahtinen45k3829 Oct 2024
Note that the label instructions differ between agents on precisely this point. – h_pergande 6 months ago
add a comment

3 Answers

Sorted by votes
66

Worth being precise here: degradation is not one process, and which one dominates depends on the condition you are asking about. In solution at refrigerated temperature the rate-limiting pathway is usually deamidation and hydrolysis; at room temperature aggregation overtakes them; frozen, the damage happens during the transitions rather than during the hold.

The temperature dependence is roughly Arrhenius over the range that matters, which in practice means every ten degrees of increase roughly doubles to triples the rate. Ten days at thirty degrees is therefore comparable to something on the order of a month or two at four degrees — bad, but not the catastrophe it feels like when you open a warm parcel.

On the detail: aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.

The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.

If the material arrived warm and it was lyophilised, test it and proceed on the result. If it arrived warm and it was in solution, the result is more likely to be interesting than reassuring.

edited 13 Feb 2025 by Dr_Yusuf_Adeyemi — tightened the wording; no substantive change

shareimprove this answerflag
DA
answeredDr_Yusuf_Adeyemi95k24830 Jan 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
45

Stated carefully, freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.

Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.

Worth being precise here: light matters for specific residues rather than in general. Tryptophan and to a lesser extent tyrosine and methionine are photo-labile; a sequence without them is largely indifferent to ambient light over the timescales in question. Amber glass is cheap insurance rather than a requirement.

I would be careful about generalising across sequences. Stability is sequence-specific, and a rule derived from semaglutide will not transfer cleanly to a tri-agonist with different residues in different local environments.

The single highest-value change most people can make is buying a cheap logging thermometer, because it converts an assumption about their storage into a record.

edited 13 Feb 2025 by Dr_Aoife_Brennan — updated for the 2026 guidance change

shareimprove this answerflag
DB
answeredDr_Aoife_Brennan50k4819 Jan 2025
35

Concretely, the lyophilised solid is far more robust than anything anyone says about it, and the solution is far less robust. Most of the confusion in this area comes from advice about one being applied to the other.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

To be exact about it, for the solid state, residual moisture is the dominant variable. A cake at two per cent water is considerably more stable than the same cake at six per cent, because water is both a reactant in hydrolysis and a plasticiser that lowers the glass transition temperature. This is why a desiccant in the outer packaging is not theatre, and why opening a cold vial in a humid room is a genuine error — you condense water onto the cake.

Worth stating: research-use-only material has no stability programme behind it at all, so any beyond-use date you apply is your own construct.

The practical rule is that time and temperature multiply, so shorten whichever one you control.

shareimprove this answerflag
PO
answeredpip_okonjo11k1622 Feb 2025
4Any reason this would differ for a longer peptide? – plate_count_9k 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.